```
=> d his ful

     (FILE 'HOME' ENTERED AT 15:55:44 ON 06 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 15:55:57 ON 06 MAR 2006
L1             STRUCTURE UPLOADED
               D L1
L2           36 SEA SSS SAM L1
L3         4257 SEA SSS FUL L1
L4             STRUCTURE UPLOADED
               D
L5           77 SEA SUB=L3 SSS FUL L4

     FILE 'HCAPLUS, USPATFULL, USPAT2, TOXCENTER' ENTERED AT 15:59:24 ON 06
     MAR 2006
L6           26 SEA PLU=ON  L5
L7           19 DUP REM L6 (7 DUPLICATES REMOVED)
                    ANSWERS '1-15' FROM FILE HCAPLUS
                    ANSWERS '16-19' FROM FILE USPATFULL
L8           15 SEA PLU=ON  L7 AND (PD<20020910 OR PRD<20020910)
L9            6 SEA PLU=ON  L7 AND (PD<20010910)
L10           9 SEA PLU=ON  L8 NOT L9
               D L9 1-6 IBIB HITSTR
               D L10 1-9 IBIB HITSTR


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    5 MAR 2006  HIGHEST RN 875875-45-9
     DICTIONARY FILE UPDATES:   5 MAR 2006  HIGHEST RN 875875-45-9

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html
```

FILE HCAPLUS
FILE COVERS 1907 - 6 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 5 Mar 2006 (20060305/ED)

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 2 Mar 2006 (20060302/PD)
FILE LAST UPDATED: 2 Mar 2006 (20060302/ED)
CA INDEXING IS CURRENT THROUGH 28 Feb 2006 (20060228/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Mar 2006 (20060302/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005

FILE USPAT2
FILE COVERS 2001 TO PUBLICATION DATE: 2 Mar 2006 (20060302/PD)
FILE LAST UPDATED: 2 Mar 2006 (20060302/ED)
CA INDEXING IS CURRENT THROUGH 28 Feb 2006 (20060228/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Mar 2006 (20060302/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005

FILE TOXCENTER
FILE COVERS 1907 TO 28 Feb 2006 (20060228/ED)

=> d que sta
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 4257 SEA FILE=REGISTRY SSS FUL L1
L4 STR



Structure attributes must be viewed using STN Express query preparation.

L5	77	SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L6	26	SEA L5
L7	19	DUP REM L6 (7 DUPLICATES REMOVED)
L8	15	SEA L7 AND (PD<20020910 OR PRD<20020910)
L9	6	SEA L7 AND (PD<20010910)
L10	9	SEA L8 NOT L9

H:\STN queries\10798218a.str





chain nodes :
1 2 3 6 7 8 9 10 11 12 13 22
ring nodes :
4 5 14 15 16 17 18 19 23 24 25 26 27 28
chain bonds :
1-2 2-3 2-13 3-4 3-7 5-6 6-8 6-9 9-10 10-11 10-22 11-12 13-14
22-23
ring bonds :
4-5 14-15 14-19 15-16 16-17 17-18 18-19 23-24 23-28 24-25 25-26
26-27 27-28
exact/norm bonds :
1-2 2-3 2-13 3-4 3-7 4-5 5-6 6-8 6-9 9-10 10-11 10-22 11-12
13-14 14-15 14-19 15-16 16-17 17-18 18-19 22-23 23-24 23-28 24-25
25-26 26-27 27-28

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom
17:Atom 18:Atom 19:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom
27:Atom 28:Atom

H:\STN queries\10798218b.str





chain nodes :
1 2 3 6 7 8 9 10 11 12 13 22
ring nodes :
4 5 14 15 16 17 18 19 23 24 25 26 27 28
chain bonds :
1-2 2-3 2-13 3-4 3-7 5-6 6-8 6-9 9-10 10-11 10-22 11-12 13-14
22-23
ring bonds :
4-5 14-15 14-19 15-16 16-17 17-18 18-19 23-24 23-28 24-25 25-26
26-27 27-28
exact/norm bonds :
1-2 2-3 2-13 3-4 3-7 4-5 5-6 6-8 6-9 9-10 10-11 10-22 11-12
13-14 14-15 14-19 15-16 16-17 17-18 18-19 22-23 23-24 23-28 24-25
25-26 26-27 27-28

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom
17:Atom 18:Atom 19:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom
27:Atom 28:Atom

=> d l9 1-6 ibib hitstr

L9 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:311742 HCAPLUS
DOCUMENT NUMBER: 135:606
TITLE: High potency analogs of apelin, a ligand of orphan GPCR APJ
AUTHOR(S): Nishizawa, Naoki; Hosoya, Masaki; Kitada, Chieko; Hinuma, Shuji; Onda, Haruo; Nishimura, Osamu; Fujino, Masahiko
CORPORATE SOURCE: Discovery Research Laboratories I, Takeda Chemical Industries, Ltd., Ibaraki, 300-4293, Japan
SOURCE: Peptide Science (**2001**), Volume Date 2000, 37th, 151-154
CODEN: PSCIFQ; ISSN: 1344-7661
PUBLISHER: Japanese Peptide Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **342381-36-6P 342381-39-9P 342381-41-3P**
342381-43-5P 342381-44-6P 342381-45-7P
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(high potency analogs of apelin ligand of orphan GPCR APJ)
RN 342381-36-6 HCAPLUS
CN L-Phenylalanine, L-glutaminyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-39-9 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-phenylalanyl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-41-3 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-43-5 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-44-6 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-phenylalanyl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-45-7 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

—Cl

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:227678 HCAPLUS
DOCUMENT NUMBER: 132:279545
TITLE: Preparation of peptide derivatives with binding activity for APJ receptor
INVENTOR(S): Kitada, Chieko; Hinuma, Shuji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018793	A1	20000406	WO 1999-JP5216	19990924 <--
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9957593	A1	20000417	AU 1999-57593	19990922 <--
CA 2343924	AA	20000406	CA 1999-2343924	19990924 <--
JP 2000159795	A2	20000613	JP 1999-270419	19990924 <--
EP 1116727	A1	20010718	EP 1999-944809	19990924 <--

EP 1116727 B1 20030319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
AT 234859 E 20030415 AT 1999-944809 19990924
PRIORITY APPLN. INFO.: JP 1998-271626 A 19980925
WO 1999-JP5216 W 19990924

OTHER SOURCE(S): MARPAT 132:279545

IT **263247-99-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide derivs. as APJ receptor ligands and drugs)

RN 263247-99-0 HCAPLUS

CN L-Phenylalanine, 5-oxo-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:102472 HCAPLUS
DOCUMENT NUMBER: 118:102472
TITLE: Preparation of hexa- and heptapeptide anaphylatoxin-receptor ligands
INVENTOR(S): Wiedeman, Paul E.; Kawai, Megumi; Luly, Jay R.; Or, Yat Sun; Wagner, Rolf
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9211858	A1	19920723	WO 1991-US9319	19911210 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US 5386011	A	19950131	US 1990-634641	19901227 <--
CA 2095359	AA	19920628	CA 1991-2095359	19911210 <--
EP 564588	A1	19931013	EP 1992-903749	19911210 <--
EP 564588	B1	19970212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 148891	E	19970215	AT 1992-903749	19911210 <--

PRIORITY APPLN. INFO.: US 1990-634641 A 19901227
WO 1991-US9319 W 19911210

OTHER SOURCE(S): MARPAT 118:102472
IT **144570-53-6P 144570-77-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as anaphylatoxin receptor ligand)
RN 144570-53-6 HCAPLUS
CN D-Arginine, N2-[3-cyclohexyl-N-[3-cyclohexyl-N-[1-[3-cyclohexyl-N-(N-methyl-L-phenylalanyl)-L-alanyl]-L-prolyl]-D-alanyl]-L-alanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144570-77-4 HCAPLUS
CN D-Arginine, N2-[N-[3-cyclohexyl-N-[1-[3-cyclohexyl-N-(N-methyl-L-phenylalanyl)-L-alanyl]-L-prolyl]-D-alanyl]-L-phenylalanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:32520 HCAPLUS
DOCUMENT NUMBER: 118:32520
TITLE: Design of potent substrate-analog inhibitors of canine renin
AUTHOR(S): Hui, K. Y.; Siragy, H. M.; Haber, E.
CORPORATE SOURCE: Cardiac Unit, Massachusetts Gen. Hosp., Boston, MA, USA
SOURCE: International Journal of Peptide & Protein Research (**1992**), 40(2), 152-60
CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **115305-64-1**
RL: BIOL (Biological study)
(renin inhibition by, structure in relation to)
RN 115305-64-1 HCAPLUS
CN L-Phenylalaninamide, N-[4-[[N-[N-[1-(N-acetyl-3-cyclohexyl-L-alanyl)-L-prolyl]-L-phenylalanyl]-L-valyl]amino]-3-hydroxy-6-methyl-1-oxoheptyl]-L-leucyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



L9 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:493591 HCAPLUS
DOCUMENT NUMBER: 109:93591
TITLE: Design of rat renin inhibitory peptides
AUTHOR(S): Hui, Kwan Y.; Holtzman, Eliezer J.; Quinones, Michael A.; Hollenberg, Norman K.; Haber, Edgar
CORPORATE SOURCE: Cardiac Unit, Massachusetts Gen. Hosp., Boston, MA, 02114, USA
SOURCE: Journal of Medicinal Chemistry (**1988**), 31(9), 1679-86
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **115305-64-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and renin inhibitory activity of)
RN 115305-64-1 HCAPLUS
CN L-Phenylalaninamide, N-[4-[[N-[N-[1-(N-acetyl-3-cyclohexyl-L-alanyl)-L-prolyl]-L-phenylalanyl]-L-valyl]amino]-3-hydroxy-6-methyl-1-oxoheptyl]-L-leucyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 6 USPATFULL on STN
ACCESSION NUMBER: 95:9801 USPATFULL
TITLE: Hexapeptide anaphylatoxin-receptor ligands
INVENTOR(S): Wiedeman, Paul E., Libertyville, IL, United States
Kawai, Megumi, Libertyville, IL, United States
Luly, Jay R., Libertyville, IL, United States
Or, Yat S., Libertyville, IL, United States
Wagner, Rolf, Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5386011		19950131	<--
APPLICATION INFO.:	US 1990-634641		19901227 (7)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Davenport, A. M.
LEGAL REPRESENTATIVE: Janssen, Jerry F.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 3779
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **144570-53-6P 144570-77-4P**
(preparation of, as anaphylatoxin receptor ligand)
RN 144570-53-6 USPATFULL
CN D-Arginine, N2-[3-cyclohexyl-N-[3-cyclohexyl-N-[1-[3-cyclohexyl-N-(N-methyl-L-phenylalanyl)-L-alanyl]-L-prolyl]-D-alanyl]-L-alanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144570-77-4 USPATFULL
CN D-Arginine, N2-[N-[3-cyclohexyl-N-[1-[3-cyclohexyl-N-(N-methyl-L-phenylalanyl)-L-alanyl]-L-prolyl]-D-alanyl]-L-phenylalanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d l10 1-9 ibib hitstr

L10 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:912843 HCAPLUS
DOCUMENT NUMBER: 139:381756
TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; Mccormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 629 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2003216325	A1	20031120	US 2001-908955		20010719	<--
US 2004254117	A9	20041216				
CN 1498224	A	20040519	CN 2001-813111		20010719	<--
ZA 2002010312	A	20040329	ZA 2002-10312		20021219	<--
PRIORITY APPLN. INFO.:			US 2000-220108P	P	20000721	<--

OTHER SOURCE(S): MARPAT 139:381756
IT **394734-49-7P 395646-15-8P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)
RN 394734-49-7 HCAPLUS
CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-β-amino-α-oxobenzenebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395646-15-8 HCAPLUS
CN Carbamic acid, [(1S)-2-[(2S)-2-[[[3-amino-1-(cyclohexylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:644386 HCAPLUS
DOCUMENT NUMBER: 139:191421
TITLE: Pharmaceuticals, chymase inhibitors, and inhibitors for increased vascular permeability, containing pyrrolidine-containing peptides
INVENTOR(S): Deguchi, Takashi; Shiratake, Ryotaro; Sato, Fuminori; Fujitani, Takekazu; Honda, Yayoi; Kiyoshi, Akihiko; Notake, Mitsue; Showell, Graham Andrew; Boyle, Robert George; Klair, Sukhbinder Singh
PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003231645	A2	20030819	JP 2002-29496	20020206 <--

PRIORITY APPLN. INFO.: JP 2002-29496 20020206 <--
OTHER SOURCE(S): MARPAT 139:191421
IT **402733-16-8P 402733-17-9P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidine-containing tripeptides for pharmaceuticals which inhibit chymase and increased vascular permeability)
RN 402733-16-8 HCAPLUS
CN L-Prolinamide, N-[[3-(carboxymethyl)-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-3-cyclohexyl-L-alanyl-N-[(1S)-3,3,3-trifluoro-2-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402733-17-9 HCAPLUS
CN L-Prolinamide, 3-cyclohexyl-N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-L-alanyl-N-[(1S)-3,3,3-trifluoro-2-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:591204 HCAPLUS
DOCUMENT NUMBER: 139:149928
TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhn, Viyyoor M.; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, George F.; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Wong, Jesse K.; Nair, Latha G.
PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.; Dendreon Corp.
SOURCE: PCT Int. Appl., 633 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062265	A2	20030731	WO 2003-US1430	20030116 <--
WO 2003062265	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473032	AA	20030731	CA 2003-2473032	20030116 <--
EP 1481000	A2	20041201	EP 2003-731956	20030116 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003006931	A	20050419	BR 2003-6931	20030116 <--
JP 2005524628	T2	20050818	JP 2003-562142	20030116 <--
NO 2004002792	A	20041015	NO 2004-2792	20040702 <--
PRIORITY APPLN. INFO.:			US 2002-52386 A	20020118 <--
			WO 2003-US1430 W	20030116

OTHER SOURCE(S): MARPAT 139:149928

IT **394734-49-7P 395646-15-8P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394734-49-7 HCAPLUS
CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-β-amino-α-oxobenzenebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395646-15-8 HCAPLUS
CN Carbamic acid, [(1S)-2-[(2S)-2-[[[3-amino-1-(cyclohexylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:221711 HCAPLUS
DOCUMENT NUMBER: 138:238448
TITLE: Synthesis of peptides for use as thrombin inhibitors for therapeutic use
INVENTOR(S): Thurk, Marcel
PATENT ASSIGNEE(S): Novel Science International Gmbh, Germany
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022873	A1	20030320	WO 2002-EP10137	20020910 <--
WO 2003022873	C2	20031211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10146632	A1	20050203	DE 2001-10146632	20010921
DE 10156995	A1	20050210	DE 2001-10156995	20011121
DE 10200666	A1	20050630	DE 2002-10200666	20020110
CA 2460300	AA	20030320	CA 2002-2460300	20020910 <--
EP 1425296	A1	20040609	EP 2002-797977	20020910 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005026843	A1	20050203	US 2004-798218	20040310 <--

PRIORITY APPLN. INFO.:
DE 2001-10144340 A 20010910 <--
DE 2001-10146632 A 20010921 <--
DE 2001-10149678 A 20011009 <--

DE 2001-10156995 A 20011121 <--
DE 2002-10200666 A 20020110 <--
WO 2002-EP10137 W 20020910

OTHER SOURCE(S): MARPAT 138:238448

IT **501937-36-6P 501937-40-2P 501937-41-3P**
501937-42-4P 501937-43-5P 501937-44-6P
501937-45-7P 501937-46-8P 501937-47-9P
501937-48-0P 501937-49-1P 501937-50-4P
501937-51-5P 501937-52-6P 501937-53-7P
501937-54-8P 501937-55-9P 501937-56-0P
501937-57-1P 501937-58-2P 501937-60-6P
501937-61-7P 501937-62-8P 501937-63-9P
501937-64-0P 501937-65-1P 501937-66-2P
501937-67-3P 501937-68-4P 501937-69-5P
501937-70-8P 501937-71-9P 501937-72-0P
501937-73-1P 501937-74-2P 501948-58-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides for use as thrombin inhibitors for therapeutic use)

RN 501937-36-6 HCAPLUS
CN L-Argininamide, N2-acetyl-L-arginyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-40-2 HCAPLUS
CN L-Argininamide, N-acetyl-D-valyl-L-alanyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-41-3 HCAPLUS
CN L-Argininamide, N-acetyl-L-α-aspartyl-L-seryl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-42-4 HCAPLUS
CN L-Argininamide, N-acetyl-L-isoleucyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-43-5 HCAPLUS
CN L-Argininamide, N-acetyl-D-valyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-44-6 HCAPLUS
CN L-Argininamide, N-acetyl-L-seryl-L-seryl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-45-7 HCAPLUS
CN L-Argininamide, N2-acetyl-D-lysyl-D-prolyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 501937-46-8 HCAPLUS
CN L-Argininamide, N-acetyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 501937-47-9 HCAPLUS
CN L-Argininamide, N-acetyl-L-seryl-D-valyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-48-0 HCAPLUS
CN L-Argininamide, N-acetyl-L-seryl-L-alanyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-49-1 HCAPLUS
CN L-Argininamide, N-acetyl-L-seryl-L-arginyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

RN 501937-50-4 HCAPLUS
CN L-Argininamide, N-acetyl-L-seryl-3-cyclohexyl-L-alanyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-51-5 HCAPLUS
CN L-Argininamide, N2-acetyl-D-lysyl-L-norleucyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-52-6 HCAPLUS
CN L-Argininamide, N-acetyl-L-seryl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-53-7 HCAPLUS
CN L-Argininamide, N-acetyl-L-seryl-D-α-glutamyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-54-8 HCAPLUS
CN L-Argininamide, N-acetyl-D-tyrosyl-3-cyclohexyl-L-alanyl-D-prolyl-D-

tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-55-9 HCAPLUS
CN L-Argininamide, N2-acetyl-D-glutaminyl-D-histidyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-56-0 HCAPLUS
CN L-Argininamide, N-acetyl-D-α-glutamyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-57-1 HCAPLUS
CN L-Argininamide, N-acetyl-D-valyl-D-histidyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-58-2 HCAPLUS
CN L-Argininamide, N-acetyl-L-alanyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-60-6 HCAPLUS
CN L-Argininamide, N-acetyl-L-isoleucyl-L-arginyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 501937-61-7 HCAPLUS
CN L-Argininamide, N-acetyl-L-tryptophyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 501937-62-8 HCAPLUS
CN L-Argininamide, N-acetyl-L-tyrosyl-D-prolyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-63-9 HCAPLUS
CN L-Argininamide, N-acetyl-L-alanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-64-0 HCAPLUS
CN L-Lysinamide, N-acetyl-L-alanyl-3-cyclohexyl-D-alanyl-L-prolyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-65-1 HCAPLUS
CN L-Lysinamide, N-acetyl-L-alanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-66-2 HCAPLUS
CN L-Lysinamide, N-acetyl-L-tryptophyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 501937-67-3 HCAPLUS
CN L-Lysinamide, N-acetyl-D-phenylalanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-68-4 HCAPLUS
CN L-Lysinamide, (3S)-2-acetyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 501937-69-5 HCAPLUS
CN L-Lysinamide, (3S)-2-acetyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-70-8 HCAPLUS
CN L-Lysinamide, N-acetyl-3-(2-thienyl)-L-alanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-71-9 HCAPLUS
CN L-Lysinamide, (2S)-N-acetyl-2-phenylglycyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-72-0 HCAPLUS
CN L-Lysinamide, N-acetyl-L-norleucyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-73-1 HCAPLUS
CN L-Lysinamide, N-acetyl-3-cyclohexyl-L-alanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-74-2 HCAPLUS
CN L-Lysinamide, N-acetyl-4-nitro-L-phenylalanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NO_2

RN 501948-58-9 HCAPLUS
CN L-Lysinamide, N-acetyl-ar,ar-dichloro-L-phenylalanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A

2 (D1—Cl)

PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:171894 HCAPLUS
DOCUMENT NUMBER: 136:217051
TITLE: Preparation of proline derivatives for use as chymase inhibitor
INVENTOR(S): Deguchi, Takashi; Shiratake, Ryotaro; Sato, Fuminori; Fujitani, Buichi; Honda, Yayoi; Kiyoshi, Akihiko; Notake, Mitsue; Showell, Graham Andrew; Boyle, Robert George; Klair, Sukhbinder Singh
PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018378	A1	20020307	WO 2001-JP7137	20010821 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418041	AA	20020307	CA 2001-2418041	20010821 <--
AU 2001078782	A5	20020313	AU 2001-78782	20010821 <--
EP 1313730	A1	20030528	EP 2001-956986	20010821 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507539	T2	20040311	JP 2002-523893	20010821 <--
US 2004102384	A1	20040527	US 2003-363036	20030228 <--
US 6852744	B2	20050208		

PRIORITY APPLN. INFO.: GB 2000-21315 A 20000830 <--
WO 2001-JP7137 W 20010821 <--
OTHER SOURCE(S): MARPAT 136:217051

IT **402733-16-8P 402733-17-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of proline derivs. for use as chymase inhibitors)
RN 402733-16-8 HCAPLUS
CN L-Prolinamide, N-[[3-(carboxymethyl)-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-3-cyclohexyl-L-alanyl-N-[(1S)-3,3,3-trifluoro-2-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402733-17-9 HCAPLUS
CN L-Prolinamide, 3-cyclohexyl-N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-L-alanyl-N-[(1S)-3,3,3-trifluoro-2-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:90062 HCAPLUS
DOCUMENT NUMBER: 136:167698
TITLE: Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-Tsung; Zhu,

Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal N.; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 536 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008244	A2	20020131	WO 2001-US22678	20010719 <--
WO 2002008244	A3	20030619		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2410662	AA	20020131	CA 2001-2410662	20010719 <--
AU 2001076988	A5	20020205	AU 2001-76988	20010719 <--
BR 2001012540	A	20030624	BR 2001-12540	20010719 <--
EP 1385870	A2	20040204	EP 2001-954764	20010719 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004504404	T2	20040212	JP 2002-514149	20010719 <--
CN 1498224	A	20040519	CN 2001-813111	20010719 <--
NZ 523782	A	20051028	NZ 2001-523782	20010719 <--
ZA 2002010312	A	20040329	ZA 2002-10312	20021219 <--
NO 2003000272	A	20030321	NO 2003-272	20030120 <--
PRIORITY APPLN. INFO.:			US 2000-220108P P	20000721 <--
			WO 2001-US22678 W	20010719 <--

OTHER SOURCE(S): MARPAT 136:167698

IT **394734-49-7P 395646-15-8P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394734-49-7 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-β-amino-α-oxobenzenebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 395646-15-8 HCAPLUS
CN Carbamic acid, [(1S)-2-[(2S)-2-[[[3-amino-1-(cyclohexylmethyl)-2,3-dioxopropyl]amino]carbonyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:713376 HCAPLUS
DOCUMENT NUMBER: 135:283216
TITLE: Peptide derivatives recognized as ligands by G protein-coupled receptor protein
INVENTOR(S): Kitada, Chieko; Nishizawa, Naoki; Hinuma, Shuji; Hosoya, Masaki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., USA
SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070769	A1	20010927	WO 2001-JP2278	20010322 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2403447	AA	20010927	CA 2001-2403447		20010322 <--
AU 2001042749	A5	20011003	AU 2001-42749		20010322 <--
EP 1270585	A1	20030102	EP 2001-915695		20010322 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2002167397	A2	20020611	JP 2001-84010		20010323 <--
US 2004116336	A1	20040617	US 2002-239321		20020919 <--
PRIORITY APPLN. INFO.:			JP 2000-87114	A	20000323 <--
			JP 2000-288891	A	20000919 <--
			WO 2001-JP2278	W	20010322 <--

IT **263247-99-0P 342381-39-9P 342381-41-3P**
342381-43-5P 342381-44-6P 342381-45-7P
362479-33-2P 362479-37-6P 362479-73-0P
362479-74-1P 362479-75-2P 362479-80-9P
362479-81-0P 362479-82-1P 362479-83-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide derivs. recognized as ligands by G protein-coupled receptor protein for pharmaceutical usage)

RN 263247-99-0 HCAPLUS

CN L-Phenylalanine, 5-oxo-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-39-9 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-phenylalanyl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-41-3 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-43-5 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-44-6 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-phenylalanyl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342381-45-7 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

—Cl

RN 362479-33-2 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C





PAGE 2-C

RN 362479-37-6 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-phenylalanyl-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

—Cl

RN 362479-73-0 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-alanylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 362479-74-1 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-alanyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 362479-75-2 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-alanyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 362479-80-9 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-3-amino-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

—Cl

RN 362479-81-0 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-3-(acetylamino)-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

—Cl

RN 362479-82-1 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-3-[(1-oxohexyl)amino]-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

—Cl

RN 362479-83-2 HCAPLUS
CN L-Phenylalanine, L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-3-[(5-carboxy-1-oxopentyl)amino]-L-alanyl-L-arginylglycyl-L-prolyl-3-cyclohexyl-L-alanyl-L-prolyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



C1

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:31406 USPATFULL
TITLE: Organic compounds with biological activity as thrombin inhibitors and use thereof
INVENTOR(S): Thurk, Marcel, Bovenden, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Novel Science International GMBH, Gottingen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005026843	A1	20050203	
APPLICATION INFO.:	US 2004-798218	A1	20040310	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-EP10137, filed on 10 Sep 2002, UNKNOWN			
	NUMBER	DATE		
PRIORITY INFORMATION:	DE 2001-144340	20010910		<--
	DE 2001-146632	20010921		<--
	DE 2001-149678	20011009		<--
	DE 2001-156995	20011121		<--
	DE 2002-10200666	20020110		<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 1928
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **501937-36-6P 501937-40-2P 501937-41-3P**
501937-42-4P 501937-43-5P 501937-44-6P
501937-45-7P 501937-46-8P 501937-47-9P
501937-48-0P 501937-49-1P 501937-50-4P
501937-51-5P 501937-52-6P 501937-53-7P
501937-54-8P 501937-55-9P 501937-56-0P
501937-57-1P 501937-58-2P 501937-60-6P
501937-61-7P 501937-62-8P 501937-63-9P
501937-64-0P 501937-65-1P 501937-66-2P
501937-67-3P 501937-68-4P 501937-69-5P
501937-70-8P 501937-71-9P 501937-72-0P

501937-73-1P 501937-74-2P 501948-58-9P
(preparation of peptides for use as thrombin inhibitors for therapeutic use)

RN 501937-36-6 USPATFULL
CN L-Argininamide, N2-acetyl-L-arginyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-40-2 USPATFULL
CN L-Argininamide, N-acetyl-D-valyl-L-alanyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-41-3 USPATFULL
CN L-Argininamide, N-acetyl-L-α-aspartyl-L-seryl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-42-4 USPATFULL
CN L-Argininamide, N-acetyl-L-isoleucyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-43-5 USPATFULL
CN L-Argininamide, N-acetyl-D-valyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-44-6 USPATFULL

CN L-Argininamide, N-acetyl-L-seryl-L-seryl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-45-7 USPATFULL
CN L-Argininamide, N2-acetyl-D-lysyl-D-prolyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 501937-46-8 USPATFULL
CN L-Argininamide, N-acetyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 501937-47-9 USPATFULL
CN L-Argininamide, N-acetyl-L-seryl-D-valyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-48-0 USPATFULL
CN L-Argininamide, N-acetyl-L-seryl-L-alanyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-49-1 USPATFULL
CN L-Argininamide, N-acetyl-L-seryl-L-arginyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

RN 501937-50-4 USPATFULL
CN L-Argininamide, N-acetyl-L-seryl-3-cyclohexyl-L-alanyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-51-5 USPATFULL
CN L-Argininamide, N2-acetyl-D-lysyl-L-norleucyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-52-6 USPATFULL
CN L-Argininamide, N-acetyl-L-seryl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-53-7 USPATFULL
CN L-Argininamide, N-acetyl-L-seryl-D-α-glutamyl-3-cyclohexyl-L-alanyl-

D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-54-8 USPATFULL
CN L-Argininamide, N-acetyl-D-tyrosyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-55-9 USPATFULL
CN L-Argininamide, N2-acetyl-D-glutaminyl-D-histidyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-56-0 USPATFULL
CN L-Argininamide, N-acetyl-D-α-glutamyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-57-1 USPATFULL
CN L-Argininamide, N-acetyl-D-valyl-D-histidyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-58-2 USPATFULL
CN L-Argininamide, N-acetyl-L-alanyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-60-6 USPATFULL
CN L-Argininamide, N-acetyl-L-isoleucyl-L-arginyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 501937-61-7 USPATFULL
CN L-Argininamide, N-acetyl-L-tryptophyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 501937-62-8 USPATFULL
CN L-Argininamide, N-acetyl-L-tyrosyl-D-prolyl-3-cyclohexyl-L-alanyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-63-9 USPATFULL
CN L-Argininamide, N-acetyl-L-alanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-64-0 USPATFULL
CN L-Lysinamide, N-acetyl-L-alanyl-3-cyclohexyl-D-alanyl-L-prolyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-65-1 USPATFULL
CN L-Lysinamide, N-acetyl-L-alanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-66-2 USPATFULL

CN L-Lysinamide, N-acetyl-L-tryptophyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 501937-67-3 USPATFULL

CN L-Lysinamide, N-acetyl-D-phenylalanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-68-4 USPATFULL
CN L-Lysinamide, (3S)-2-acetyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 501937-69-5 USPATFULL
CN L-Lysinamide, (3S)-2-acetyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-

(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-70-8 USPATFULL
CN L-Lysinamide, N-acetyl-3-(2-thienyl)-L-alanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-71-9 USPATFULL
CN L-Lysinamide, (2S)-N-acetyl-2-phenylglycyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-72-0 USPATFULL
CN L-Lysinamide, N-acetyl-L-norleucyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-73-1 USPATFULL
CN L-Lysinamide, N-acetyl-3-cyclohexyl-L-alanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501937-74-2 USPATFULL
CN L-Lysinamide, N-acetyl-4-nitro-L-phenylalanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 501948-58-9 USPATFULL
CN L-Lysinamide, N-acetyl-ar,ar-dichloro-L-phenylalanyl-3-cyclohexyl-D-alanyl-(2S)-2-azetidinecarbonyl-D-tyrosyl-N6-(aminoiminomethyl)- (9CI) (CA

INDEX NAME)

PAGE 1-A

2 (D1—C1)

PAGE 2-A



L10 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER:	2004:133847 USPATFULL
TITLE:	Pyrrolidine derivatives and their use as chymase inhibitor
INVENTOR(S):	Deguchi, Takashi, Kobe-shi, JAPAN Shiratake, Ryotaro, Osaka-shi, JAPAN Sato, Fuminori, Kobe-shi, JAPAN Fujitani, Buichi, Sakai-shi, JAPAN Honda, Yayoi, Ibaraki-shi, JAPAN Kiyoshi, Akihiko, Kobe-shi, JAPAN Notake, Mitsue, Suita-shi, JAPAN Showell, Graham Andrew, Lackford, UNITED KINGDOM Boyle, Robert George, Cambridge, UNITED KINGDOM Klair, Sukhbinder Singh, Linton, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004102384	A1	20040527	
	US 6852744	B2	20050208	
APPLICATION INFO.:	US 2003-363036	A1	20030228	(10)
	WO 2001-JP7137		20010821	

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2000-21315	20000830	<--
DOCUMENT TYPE:	Utility		

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1970
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **402733-16-8P 402733-17-9P**
(preparation of proline derivs. for use as chymase inhibitors)
RN 402733-16-8 USPATFULL
CN L-Prolinamide, N-[[3-(carboxymethyl)-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-3-cyclohexyl-L-alanyl-N-[(1S)-3,3,3-trifluoro-2-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402733-17-9 USPATFULL
CN L-Prolinamide, 3-cyclohexyl-N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-L-alanyl-N-[(1S)-3,3,3-trifluoro-2-oxo-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.